@article{c3d22bcb057e4374a3657620ad327fb3,
title = "Metastasis-directed therapy in prostate cancer: Why, when, and how?",
abstract = "Metastatic prostate cancer remains a life-limiting disease; while we have seen significant advances in systemic approaches which form the backbone of management, no curative paradigm yet exists. Metastasis-directed therapy (MDT) with stereotactic ablative radiotherapy (SABR) has emerged as a promising complementary technique for the management of low-volume metastatic prostate cancer. Herein we will review the rationale, potential benefits, and practical considerations associated with this approach.",
author = "Phillips, {Ryan M.} and Deek, {Matthew P.} and DeWeese, {Theodore L.} and Tran, {Phuoc T.}",
note = "Funding Information: ACKNOWLEDGEMENTS: Dr. Phillips is funded by the RSNA. Dr. Tran is funded by the Nesbitt-McMaster Foundation, Ronald Rose and Joan Lazar, Movember-PCF and the NIH (R01CA166348, U01CA2120007 & R21CA223403). Funding Information: consulting fees and honoraria from RefleXion Medical, Inc., research funding from RefleXion Medical, Inc, Astellas Pharm., and Bayer Healthcare. He is co-owner of Patent#: 9114158 licensed to Natsar Pharm. Dr. Phillips receives consulting fees and honoraria from RefleXion Medical, Inc. The other authors have reported no significant financial relationships in connection with the topics herein. Publisher Copyright: {\textcopyright} 2019 UBM Medica Healthcare Publications. All rights reserved.",
year = "2019",
language = "English (US)",
volume = "33",
pages = "394--399",
journal = "ONCOLOGY (United States)",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "10",
}